Sites / Orlando Clinical Research Center
Is this you?

Request access for Orlando Clinical Research Center with your @ocrc.net work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Orlando Clinical Research Center

Unclaimed profile

Independent Site Network · Orlando, FL · ~1 sites

Intera lens
ICP 4Lift (cardio sample) 0.43Recruit soph 0.57
Quality Scorecard (1–100)
Overall78Recruit62Ops84Sponsor85Ther85

Performance (observed)

Historical trials
397
Completed
235
Terminated/Withdrawn
29
Completion rate
89%
Active now
127
Phase 2
103
Phase 3
168
Realized enrollment
247,112
First study year
1995
Years active
31
Match confidence
high
Enrollment velocity (inf)
7,971

Therapeutic

Areas
Phase I-IV: Diabetes, Kidney, Liver, CNS, Hypertension, Hyperlipidemia, Dermatology, Gastroenterology, Asthma, Analgesics, Anti-Infective
Specialties
Phase I-IV trials - Liver disease, Kidney disease, Hepatitis C, Diabetes, 288+ trials active/completed
Breadth (conditions)
703
States
FL

Recruitment (web observed)

Meta Pixel
Yes
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y - Blog content on AI in clinical trials
Capability notes
Active; dedicated recruitment team; patient recruitment support mentioned

Relationships

Sponsors
Gilead Sciences; National Cancer Institute (NCI); Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Children's Oncology Group
CROs
ICON Clinical Research; PPD, Part of Thermo Fisher Scientific; Premier Research; Syneos Health; Teva Branded Pharmaceutical Products R&D LLC
Owner / parent
Private; Founded 1990

Capacity & people

Investigators
Coordinators
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
tmarbury@ocrc.net

Tech & DCT

Builds tech
Unclear; has custom-built facility but vendor status unknown
Tech stack
Electronic Data Capture; digital telemetry systems
Recruiting visible
Y

Notes

Single-site Phase I-IV facility, $11.7M revenue, 30 employees. Strong inpatient capability (100 beds) with focus on Phase I trials. Advertises patient recruitment but limited innovation signals. No AI/tech mentions. Limited scalability as single site. Weak fit for Intera given single-location footprint and basic recruitment approach. [Validated: 11 active recruiting cardiometabolic trials on ClinicalTrials.gov.]

Recommendation features (sample indication)

Ind fit 1.00Liftability 0.43Overall78

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.